查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1134155

全球神經性疼痛市場 – 預測到 2027 年

Global Neuropathic Pain Market Research Report Forecast to 2027
出版日期: | 出版商: Market Research Future | 英文 208 Pages | 訂單完成後即時交付

價格

在截至 2027 年的研究期間，全球神經性疼痛市場規模預計將以 6.3% 的顯著複合年增長率增長，到 2027 年將超過 287.782 億美元。越來越多的疼痛管理中心、對仿製藥的需求不斷增加以及糖尿病的增加正在推動神經性疼痛市場的增長。

本報告研究和分析全球神經性疼痛市場，提供包括市場動態、市場分析、競爭格局和公司概況在內的系統信息。

內容

第 1 章執行摘要

第二章市場介紹

  • 定義
  • 調查範圍
  • 調查目的
  • 市場結構
  • 假設和限制

第三章研究方法

  • 數據挖掘
  • 二次調查
  • 初步調查
  • 主要受訪者的細分
  • 預測方法
  • 調查方法 尺寸估計的調查方法
    • 自下而上的方法
    • 自上而下的方法
  • 數據三角剖分
  • 驗證

第 4 章市場動態

  • 概覽
  • 驅動程序
    • 糖尿病性神經病變的患□□病率不斷上升
    • 醫療保健增加
    • 受傷和其他特定州的創傷增加
  • 限制因素
    • 假藥和治療副作用的增加
    • 缺乏對神經系統疾病的認識
  • 機會
    • 在發展中地區推出新產品

第五章市場因素分析

  • 價值鏈分析
    • 研發
    • 製造
    • 分銷和銷售
    • 售後監控
  • 波特五力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭強度
  • 分析 COVID-19 的影響
    • 概覽
    • 對正在進行的治療的影響以及因推遲而推遲的可用性
    • 對患者人數的影響

第 6 章全球神經性疼痛市場：按類型分類

  • 概覽
  • 周圍神經病變
  • 卡壓性神經病
  • 三叉神經痛
  • 幻肢痛
  • 帶狀皰疹後遺神經痛 (PHN)
  • 創傷後神經病變

第 7 章全球神經性疼痛市場：按適應症分類

  • 概覽
  • 糖尿病性神經病變
  • 椎管狹窄
  • 化療引起的周圍神經病變
  • 其他

第 8 章全球神經性疼痛市場：通過診斷

  • 概覽
  • 成像
  • 驗血
  • 體檢

第 9 章全球神經性疼痛市場：按治療分類

  • 概覽
  • 藥物
  • 多學科治療

第 10 章全球神經性疼痛市場：按分銷渠道

  • 概覽
  • 零售藥店和藥店
  • 在線藥店

第 11 章全球神經性疼痛市場：按最終用戶分類

  • 概覽
  • 醫院
  • 診所
  • 研究所

第 12 章全球神經性疼痛市場：按地區劃分

  • 概覽
  • 美洲
    • 北美
    • 拉丁美洲
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞
    • 亞太地區其他地區
  • 中東和非洲
    • 中東
    • 非洲

第 13 章競爭格局

  • 概覽
  • 競爭基準
  • 全球神經性疼痛市場：公司排名（2020 年）
  • 全球神經性疼痛市場的主要增長策略
  • 按開發項目數量劃分的主要公司
  • 競爭性基準測試：全球神經性疼痛市場
  • 主要發展和增長戰略
    • 產品批准和發布
    • 收購
  • 財務矩陣

第 14 章公司簡介

  • ABBOTT
  • PFIZER
  • JOHNSON & JOHNSON SERVICES, INC.
  • BAXTER INTERNATIONAL
  • ELI LILY AND COMPANY
  • GLAXOSMITHKLINE PLC
  • SANOFI
  • ASTRAZENECA
  • DEPOMED INC.（ASSERTIO THERAPEUTICS, INC）
  • BIOGEN, INC.
  • ASTELLAS PHARMA LTD.

第十五章附錄

  • 參考資料
  • 相關報告
Product Code: MRFR/HC/0881-CR

Global Neuropathic Pain Market Research Report - Forecast to 2027

Market analysis

Neuropathic Pain Market is anticipated to surpass USD 28,778.20 million by 2027 at a notable CAGR of 6.3% during the review period.

Neuropathic pain is prominently caused by the peripheral nerve disorder. The global market growth is attributed to the introduction of pain management centers along with higher demand for generic drugs.

In Neuropathic Pain Market, diabetes is one of the main sources of expanded neuropathic torment. The subsequent primary driver of neuropathic torment is the destructive infection called disease. According to World Health Organization (WHO) reports, in 2014, there were around 422 million individuals who were experiencing diabetes.

The huge populace is likewise viewed as one of the essential basic drivers of the market. Likewise, better treatment offices, improvement of medical care frameworks, ascend popularity of neuropathic torment and critical ventures by pharma organizations, improvement in nature of medications, and quantities of torment the board frameworks will push the market on a positive course.

Market segmentation

Based on type segment, the global neuropathic pain market has been classified into peripheral neuropathy, post-traumatic neuropathy, post-herpetic neuralgia (PHN), phantom limb pain, entrapment neuropathy, and trigeminal neuralgia. Based on indication, the market is divided into chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and spinal stenosis. In terms of diagnosis, the market is segmented into blood tests, imaging, and physical examination. Based on its treatment, the market is classified into medication type and multimodal therapy. The end-use industries include clinics, hospitals, and research organizations. Based on its distribution channels, the market is divided into online pharmacies and retail pharmacies & drug stores.

Regional analysis

The nations in North America and South America contained an all-out market esteem worth of USD 6,645.09 million in the year 2019. It is anticipated that it will arrive at a CAGR of around 5.6% during the gauge time frame. The rising number of problems connected with neuropathic torment, mechanical turns of events, and ascend in mindfulness are the fundamental elements of the Neuropathic Pain Market development.

The American market is grouped into North America and Latin America. The market of North America is additionally partitioned into the United States of America and Canada.

The neuropathic torment market in Western Europe has been isolated into France, the UK, Germany, Spain, Italy, and other European nations. The market in Asia-Pacific is sectioned into India, Japan, Australia, China, South Korea, and different nations in the Asia-Pacific area. The Market in the Middle East and African district is separated into the Middle East and Africa.

Major players

Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), among others, are some of the major players in the global neuropathic pain market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION 22
  • 2.2 SCOPE OF THE STUDY 22
  • 2.3 RESEARCH OBJECTIVE 22
  • 2.4 MARKET STRUCTURE 23
  • 2.5 ASSUMPTIONS & LIMITATIONS 24

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING 25
  • 3.2 SECONDARY RESEARCH 26
  • 3.3 PRIMARY RESEARCH 27
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 28
  • 3.5 FORECASTING TECHNIQUES 29
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 30
    • 3.6.1 BOTTOM-UP APPROACH 31
    • 3.6.2 TOP-DOWN APPROACH 31
  • 3.7 DATA TRIANGULATION 32
  • 3.8 VALIDATION 32

4 MARKET DYNAMICS

  • 4.1 OVERVIEW 33
  • 4.2 DRIVERS 34
    • 4.2.1 RISING PREVALENCE OF DIABETIC NEUROPATHY 34
    • 4.2.2 INCREASING HEALTHCARE EXPENDITURE 34
    • 4.2.3 GROWING NUMBER OF INCIDENCE OF TRAUMA FROM INJURY AND OTHER CONDITIONS 35
  • 4.3 RESTRAINTS 36
    • 4.3.1 INCREASING COUNTERFEIT DRUGS & SIDE EFFECTS OF THE THERAPEUTIC TREATMENT 36
    • 4.3.2 LACK OF AWARENESS ABOUT THE NEUROLOGICAL CONDITION 37
  • 4.4 OPPORTUNITIES 38
    • 4.4.1 NEW PRODUCT LAUNCH IN DEVELOPING REGIONS 38

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS 39
    • 5.1.1 R&D 40
    • 5.1.2 MANUFACTURING 40
    • 5.1.3 DISTRIBUTION AND SALES 40
    • 5.1.4 POST-SALES MONITORING 40
  • 5.2 PORTER'S FIVE FORCES MODEL 41
    • 5.2.1 BARGAINING POWER OF SUPPLIERS 42
    • 5.2.2 BARGAINING POWER OF BUYERS 42
    • 5.2.3 THREAT OF NEW ENTRANTS 42
    • 5.2.4 THREAT OF SUBSTITUTES 42
    • 5.2.5 INTENSITY OF RIVALRY 42
  • 5.3 IMPACT ANALYSIS OF COVID-19 ON THE GLOBAL NEUROPATHIC PAIN MARKET 43
    • 5.3.1 OVERVIEW 43
    • 5.3.2 IMPACT ON ONGOING TREATMENTS AND DELAYED AVAILABILITY DUE TO DEFERMENT 43
    • 5.3.3 IMPACT ON NUMBER OF PATIENTS 44

6 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE

  • 6.1 OVERVIEW 45
  • 6.2 PERIPHERAL NEUROPATHY 47
  • 6.3 ENTRAPMENT NEUROPATHY 47
  • 6.4 TRIGEMINAL NEURALGIA 48
  • 6.5 PHANTOM LIMB PAIN 48
  • 6.6 POST HERPETIC NEURALGIA (PHN) 49
  • 6.7 POST TRAUMATIC NEUROPATHY 49

7 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION

  • 7.1 OVERVIEW 50
  • 7.2 DIABETIC NEUROPATHY 52
  • 7.3 SPINAL STENOSIS 52
  • 7.4 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY 53
  • 7.5 OTHERS 53

8 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS

  • 8.1 OVERVIEW 54
  • 8.2 IMAGING 55
  • 8.3 BLOOD TESTS 56
  • 8.4 PHYSICAL EXAMINATION 56

9 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT

  • 9.1 OVERVIEW 57
  • 9.2 MEDICATION 58
  • 9.3 MULTIMODAL THERAPY 60

10 GLOBAL NEUROPATHIC PAIN SMARKET, BY DISTRIBUTION CHANNEL

  • 10.1 OVERVIEW 61
  • 10.2 RETAIL PHARMACIES & DRUG STORES 62
  • 10.3 ONLINE PHARMACIES 62

11 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER

  • 11.1 OVERVIEW 63
  • 11.2 HOSPITALS 64
  • 11.3 CLINICS 64
  • 11.4 RESEARCH ORGANIZATIONS 65

12 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION

  • 12.1 OVERVIEW 66
  • 12.2 AMERICAS 67
    • 12.2.1 NORTH AMERICA 72
      • 12.2.1.1 US 77
      • 12.2.1.2 CANADA 81
    • 12.2.2 LATIN AMERICA 85
  • 12.3 EUROPE 90
    • 12.3.1 WESTERN EUROPE 95
      • 12.3.1.1 GERMANY 100
      • 12.3.1.2 UK 104
      • 12.3.1.3 FRANCE 108
      • 12.3.1.4 ITALY 112
      • 12.3.1.5 SPAIN 116
      • 12.3.1.6 REST OF WESTERN EUROPE 120
    • 12.3.2 EASTERN EUROPE 124
  • 12.4 ASIA-PACIFIC 129
    • 12.4.1 CHINA 134
    • 12.4.2 INDIA 138
    • 12.4.3 JAPAN 142
    • 12.4.4 SOUTH KOREA 146
    • 12.4.5 AUSTRALIA 150
    • 12.4.6 REST OF ASIA-PACIFIC 154
  • 12.5 MIDDLE EAST & AFRICA 159
    • 12.5.1 MIDDLE EAST 164
    • 12.5.2 AFRICA 168

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW 173
  • 13.2 COMPETITIVE BENCHMARKING 174
  • 13.3 GLOBAL NEUROPATHIC PAIN MARKET: COMPANY RANKING, 2020 175
  • 13.4 MAJOR GROWTH STRATEGY IN THE GLOBAL NEUROPATHIC PAIN MARKET 175
  • 13.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 176
  • 13.6 COMPETITIVE BENCHMARKING: GLOBAL NEUROPATHIC PAIN MARKET 176
  • 13.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 177
    • 13.7.1 PRODUCT APPROVALS AND LAUNCHES 177
    • 13.7.2 ACQUISITIONS 177
  • 13.8 FINANCIAL MATRIX 178

14 COMPANY PROFILES

  • 14.1 ABBOTT 179
    • 14.1.1 COMPANY OVERVIEW 179
    • 14.1.2 FINANCIAL OVERVIEW 180
    • 14.1.3 PRODUCTS/SERVICES OFFERED 180
    • 14.1.4 KEY DEVELOPMENTS 181
    • 14.1.5 SWOT ANALYSIS 182
    • 14.1.6 KEY STRATEGIES 182
  • 14.2 PFIZER 183
    • 14.2.1 COMPANY OVERVIEW 183
    • 14.2.2 FINANCIAL OVERVIEW 183
    • 14.2.3 PRODUCTS/SERVICES OFFERED 184
    • 14.2.4 KEY DEVELOPMENTS 184
    • 14.2.5 SWOT ANALYSIS 184
    • 14.2.6 KEY STRATEGIES 184
  • 14.3 JOHNSON & JOHNSON SERVICES, INC. 185
    • 14.3.1 COMPANY OVERVIEW 185
    • 14.3.2 FINANCIAL OVERVIEW 186
    • 14.3.3 PRODUCTS/SERVICES OFFERED 186
    • 14.3.4 KEY DEVELOPMENTS 186
    • 14.3.5 SWOT ANALYSIS 187
    • 14.3.6 KEY STRATEGIES 187
  • 14.4 BAXTER INTERNATIONAL 188
    • 14.4.1 COMPANY OVERVIEW 188
    • 14.4.2 FINANCIAL OVERVIEW 188
    • 14.4.3 PRODUCTS/SERVICES OFFERED 189
    • 14.4.4 KEY DEVELOPMENTS 189
    • 14.4.5 SWOT ANALYSIS 189
    • 14.4.6 KEY STRATEGIES 190
  • 14.5 ELI LILY AND COMPANY 190
    • 14.5.1 COMPANY OVERVIEW 190
    • 14.5.2 FINANCIAL OVERVIEW 191
    • 14.5.3 PRODUCTS/SERVICES OFFERED 191
    • 14.5.4 KEY DEVELOPMENTS 191
    • 14.5.5 SWOT ANALYSIS 192
    • 14.5.6 KEY STRATEGIES 192
  • 14.6 GLAXOSMITHKLINE PLC 193
    • 14.6.1 COMPANY OVERVIEW 193
    • 14.6.2 FINANCIAL OVERVIEW 193
    • 14.6.3 PRODUCTS/SERVICES OFFERED 194
    • 14.6.4 KEY DEVELOPMENTS 194
    • 14.6.5 SWOT ANALYSIS 194
    • 14.6.6 KEY STRATEGIES 195
  • 14.7 SANOFI 195
    • 14.7.1 COMPANY OVERVIEW 195
    • 14.7.2 FINANCIAL OVERVIEW 196
    • 14.7.3 PRODUCTS/SERVICES OFFERED 196
    • 14.7.4 KEY DEVELOPMENTS 197
    • 14.7.5 SWOT ANALYSIS 197
    • 14.7.6 KEY STRATEGIES 197
  • 14.8 ASTRAZENECA 198
    • 14.8.1 COMPANY OVERVIEW 198
    • 14.8.2 FINANCIAL OVERVIEW 198
    • 14.8.3 PRODUCTS/SERVICES OFFERED 199
    • 14.8.4 KEY DEVELOPMENTS 199
    • 14.8.5 SWOT ANALYSIS 199
    • 14.8.6 KEY STRATEGIES 199
  • 14.9 DEPOMED INC. (ASSERTIO THERAPEUTICS, INC) 200
    • 14.9.1 COMPANY OVERVIEW 200
    • 14.9.2 FINANCIAL OVERVIEW 200
    • 14.9.3 PRODUCTS/SERVICES OFFERED 200
    • 14.9.4 KEY DEVELOPMENTS 201
    • 14.9.5 SWOT ANALYSIS 201
    • 14.9.6 KEY STRATEGIES 202
  • 14.10 BIOGEN, INC. 202
    • 14.10.1 COMPANY OVERVIEW 202
    • 14.10.2 FINANCIAL OVERVIEW 202
    • 14.10.3 PRODUCTS/SERVICES OFFERED 203
    • 14.10.4 KEY DEVELOPMENTS 203
    • 14.10.5 SWOT ANALYSIS 203
    • 14.10.6 KEY STRATEGIES 203
  • 14.11 ASTELLAS PHARMA LTD. 204
    • 14.11.1 COMPANY OVERVIEW 204
    • 14.11.2 FINANCIAL OVERVIEW 204
    • 14.11.3 PRODUCTS/SERVICES OFFERED 205
    • 14.11.4 KEY DEVELOPMENTS 205
    • 14.11.5 SWOT ANALYSIS 205
    • 14.11.6 KEY STRATEGIES 206

15 APPENDIX

  • 15.1 REFERENCES 207
  • 15.2 RELATED REPORTS 207

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 24
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 27
  • TABLE 3 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 46
  • TABLE 4 GLOBAL NEUROPATHIC PAIN MARKET FOR PERIPHERAL NEUROPATHY, BY REGION, 2020-2027 (USD MILLION) 47
  • TABLE 5 GLOBAL NEUROPATHIC PAIN MARKET FOR ENTRAPMENT NEUROPATHY, BY REGION, 2020-2027 (USD MILLION) 47
  • TABLE 6 GLOBAL NEUROPATHIC PAIN MARKET FOR TRIGEMINAL NEURALGIA, BY REGION, 2020-2027 (USD MILLION) 48
  • TABLE 7 GLOBAL NEUROPATHIC PAIN MARKET FOR PHANTOM LIMB PAIN, BY REGION, 2020-2027 (USD MILLION) 48
  • TABLE 8 GLOBAL NEUROPATHIC PAIN MARKET FOR POST HERPETIC NEURALGIA (PHN), BY REGION, 2020-2027 (USD MILLION) 49
  • TABLE 9 GLOBAL NEUROPATHIC PAIN MARKET FOR POST TRAUMATIC NEUROPATHY, BY REGION, 2020-2027(USD MILLION) 49
  • TABLE 10 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2029 (USD MILLION) 51
  • TABLE 11 GLOBAL NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY REGION 2020-2029 (USD MILLION) 52
  • TABLE 12 GLOBAL NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE 2020-2029 (USD MILLION) 52
  • TABLE 13 GLOBAL NEUROPATHIC PAIN MARKET, FOR SPINAL STENOSIS, BY REGION, 2020-2029 (USD MILLION) 52
  • TABLE 14 GLOBAL NEUROPATHIC PAIN MARKET, FOR CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, BY REGION 2020-2029 (USD MILLION) 53
  • TABLE 15 GLOBAL NEUROPATHIC PAIN MARKET, FOR OTHERS, BY REGION, 2020-2029 (USD MILLION) 53
  • TABLE 16 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 55
  • TABLE 17 GLOBAL NEUROPATHIC PAIN MARKET FOR IMAGING, BY REGION, 2020-2027 (USD MILLION) 55
  • TABLE 18 GLOBAL NEUROPATHIC PAIN MARKET BY IMAGING TYPE, 2020-2027 (USD MILLION) 55
  • TABLE 19 GLOBAL NEUROPATHIC PAIN MARKET FOR BLOOD TESTS, BY REGION, 2020-2027 (USD MILLION) 56
  • TABLE 20 GLOBAL NEUROPATHIC PAIN MARKET FOR PHYSICAL EXAMINATION, BY REGION, 2020-2027 (USD MILLION) 56
  • TABLE 21 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 58
  • TABLE 22 GLOBAL NEUROPATHIC PAIN MARKET FOR MEDICATION, BY REGION, 2020-2027 (USD MILLION) 58
  • TABLE 23 GLOBAL NEUROPATHIC PAIN MARKET BY MEDICATION TYPE, 2020-2027 (USD MILLION) 59
  • TABLE 24 GLOBAL NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 59
  • TABLE 25 GLOBAL NEUROPATHIC PAIN MARKET BY ANTIDEPRESSANT DRUGS, 2020-2027 (USD MILLION) 59
  • TABLE 26 GLOBAL NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 60
  • TABLE 27 GLOBAL NEUROPATHIC PAIN MARKET FOR MULTIMODAL THERAPY, BY REGION, 2020-2027 (USD MILLION) 60
  • TABLE 28 GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 62
  • TABLE 29 GLOBAL NEUROPATHIC PAIN MARKET FOR RETAIL PHARMACIES & DRUG STORES, BY REGION, 2020-2027 (USD MILLION) 62
  • TABLE 30 GLOBAL NEUROPATHIC PAIN MARKET FOR ONLINE PHARMACIES, BY REGION, 2020-2027 (USD MILLION) 62
  • TABLE 31 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 64
  • TABLE 32 GLOBAL NEUROPATHIC PAIN MARKET FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION) 64
  • TABLE 33 GLOBAL NEUROPATHIC PAIN MARKET FOR CLINICS, BY REGION, 2020-2027 (USD MILLION) 64
  • TABLE 34 GLOBAL NEUROPATHIC PAIN MARKET FOR RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION) 65
  • TABLE 35 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION, 2020-2027 (USD MILLION) 66
  • TABLE 36 AMERICAS: NEUROPATHIC PAIN MARKET, BY REGION, 2020-2027 (USD MILLION) 67
  • TABLE 37 AMERICAS: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 68
  • TABLE 38 AMERICAS: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 68
  • TABLE 39 AMERICAS: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 68
  • TABLE 40 AMERICAS: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 69
  • TABLE 41 AMERICAS: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 69
  • TABLE 42 AMERICAS: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 69
  • TABLE 43 AMERICAS: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 70
  • TABLE 44 AMERICAS: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 70
  • TABLE 45 AMERICAS: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 70
  • TABLE 46 AMERICAS: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 71
  • TABLE 47 AMERICAS: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 71
  • TABLE 48 AMERICAS: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 71
  • TABLE 49 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 73
  • TABLE 50 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 73
  • TABLE 51 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 73
  • TABLE 52 NORTH AMERICA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 74
  • TABLE 53 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 74
  • TABLE 54 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 74
  • TABLE 55 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY TREATMENT,2020-2027 (USD MILLION) 75
  • TABLE 56 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 75
  • TABLE 57 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 75
  • TABLE 58 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 76
  • TABLE 59 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 76
  • TABLE 60 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 76
  • TABLE 61 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 77
  • TABLE 62 US: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 77
  • TABLE 63 US: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 77
  • TABLE 64 US: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 78
  • TABLE 65 US: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 78
  • TABLE 66 US: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 78
  • TABLE 67 US: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 79
  • TABLE 68 US: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 79
  • TABLE 69 US: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 79
  • TABLE 70 US: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 80
  • TABLE 71 US: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 80
  • TABLE 72 US: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 80
  • TABLE 73 US: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 81
  • TABLE 74 CANADA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 81
  • TABLE 75 CANADA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 81
  • TABLE 76 CANADA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 82
  • TABLE 77 CANADA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 82
  • TABLE 78 CANADA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 82
  • TABLE 79 CANADA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 83
  • TABLE 80 CANADA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 83
  • TABLE 81 CANADA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 83
  • TABLE 82 CANADA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 84
  • TABLE 83 CANADA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 84
  • TABLE 84 CANADA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 84
  • TABLE 85 CANADA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 85
  • TABLE 86 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION), 85
  • TABLE 87 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 85
  • TABLE 88 LATIN AMERICA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 86
  • TABLE 89 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 86
  • TABLE 90 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 86
  • TABLE 91 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 87
  • TABLE 92 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 87
  • TABLE 93 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 87
  • TABLE 94 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 88
  • TABLE 95 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 88
  • TABLE 96 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 88
  • TABLE 97 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 89
  • TABLE 98 EUROPE: NEUROPATHIC PAIN MARKET, BY REGION, 2020-2027 (USD MILLION) 90
  • TABLE 99 EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 91
  • TABLE 100 EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 91
  • TABLE 101 EUROPE: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 91
  • TABLE 102 EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 92
  • TABLE 103 EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 92
  • TABLE 104 EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 92
  • TABLE 105 EUROPE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 93
  • TABLE 106 EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 93
  • TABLE 107 EUROPE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 93
  • TABLE 108 EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 94
  • TABLE 109 EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 94
  • TABLE 110 EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 94
  • TABLE 111 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 95
  • TABLE 112 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 96
  • TABLE 113 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 96
  • TABLE 114 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 97
  • TABLE 115 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 97
  • TABLE 116 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 97
  • TABLE 117 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 98
  • TABLE 118 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 98
  • TABLE 119 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 98
  • TABLE 120 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 99
  • TABLE 121 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 99
  • TABLE 122 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 99
  • TABLE 123 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 100
  • TABLE 124 GERMANY NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 100
  • TABLE 125 GERMANY: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 100
  • TABLE 126 GERMANY: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 101
  • TABLE 127 GERMANY: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 101
  • TABLE 128 GERMANY: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 101
  • TABLE 129 GERMANY: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 102
  • TABLE 130 GERMANY: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 102
  • TABLE 131 GERMANY: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 102
  • TABLE 132 GERMANY: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 103
  • TABLE 133 GERMANY: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 103
  • TABLE 134 GERMANY: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 103
  • TABLE 135 GERMANY: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 104
  • TABLE 136 UK: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 104
  • TABLE 137 UK: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 104
  • TABLE 138 UK: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 105
  • TABLE 139 UK: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 105
  • TABLE 140 UK: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 105
  • TABLE 141 UK: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 106
  • TABLE 142 UK: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 106
  • TABLE 143 UK: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 106
  • TABLE 144 UK: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 107
  • TABLE 145 UK: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 107
  • TABLE 146 UK: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 107
  • TABLE 147 UK: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 108
  • TABLE 148 FRANCE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 108
  • TABLE 149 FRANCE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 108
  • TABLE 150 FRANCE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 109
  • TABLE 151 FRANCE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 109
  • TABLE 152 FRANCE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 109
  • TABLE 153 FRANCE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 110
  • TABLE 154 FRANCE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 110
  • TABLE 155 FRANCE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 110
  • TABLE 156 FRANCE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 111
  • TABLE 157 FRANCE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 111
  • TABLE 158 FRANCE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 111
  • TABLE 159 FRANCE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 112
  • TABLE 160 ITALY: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 112
  • TABLE 161 ITALY: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 112
  • TABLE 162 ITALY: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 113
  • TABLE 163 ITALY: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 113
  • TABLE 164 ITALY: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 113
  • TABLE 165 ITALY: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 114
  • TABLE 166 ITALY: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 114
  • TABLE 167 ITALY: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 114
  • TABLE 168 ITALY: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 115
  • TABLE 169 ITALY: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 115
  • TABLE 170 ITALY: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 115
  • TABLE 171 ITALY: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 116
  • TABLE 172 SPAIN: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 116
  • TABLE 173 SPAIN: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 116
  • TABLE 174 SPAIN: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 117
  • TABLE 175 SPAIN: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 117
  • TABLE 176 SPAIN: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 117
  • TABLE 177 SPAIN: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 118
  • TABLE 178 SPAIN: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 118
  • TABLE 179 SPAIN: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 118
  • TABLE 180 SPAIN: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 119
  • TABLE 181 SPAIN: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 119
  • TABLE 182 SPAIN: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 119
  • TABLE 183 SPAIN: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 120
  • TABLE 184 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 120
  • TABLE 185 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 120
  • TABLE 186 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 121
  • TABLE 187 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 121
  • TABLE 188 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 121
  • TABLE 189 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 122
  • TABLE 190 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 122
  • TABLE 191 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 122
  • TABLE 192 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 123
  • TABLE 193 REST OF WESTERN EUROPE" NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 123
  • TABLE 194 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 123
  • TABLE 195 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 124
  • TABLE 196 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 124
  • TABLE 197 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 125
  • TABLE 198 EASTERN EUROPE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 125
  • TABLE 199 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 125
  • TABLE 200 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 126
  • TABLE 201 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 126
  • TABLE 202 EASTERN EUROPE NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 126
  • TABLE 203 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 127
  • TABLE 204 EASTERN EUROPE NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 127
  • TABLE 205 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 127
  • TABLE 206 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 128
  • TABLE 207 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 128
  • TABLE 208 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 129
  • TABLE 209 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 130
  • TABLE 210 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 130
  • TABLE 211 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 131
  • TABLE 212 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 131
  • TABLE 213 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 131
  • TABLE 214 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 132
  • TABLE 215 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 132
  • TABLE 216 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 132
  • TABLE 217 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 133
  • TABLE 218 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 133
  • TABLE 219 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 133
  • TABLE 220 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 134
  • TABLE 221 CHINA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 134
  • TABLE 222 CHINA NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 134
  • TABLE 223 CHINA NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 135
  • TABLE 224 CHINA NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 135
  • TABLE 225 CHINA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 135
  • TABLE 226 CHINA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 136
  • TABLE 227 CHINA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 136
  • TABLE 228 CHINA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 136
  • TABLE 229 CHINA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 137
  • TABLE 230 CHINA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 137
  • TABLE 231 CHINA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 137
  • TABLE 232 CHINA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 138
  • TABLE 233 INDIA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 138
  • TABLE 234 INDIA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 138
  • TABLE 235 INDIA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 139
  • TABLE 236 INDIA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 139
  • TABLE 237 INDIA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 139
  • TABLE 238 INDIA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 140
  • TABLE 239 INDIA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 140
  • TABLE 240 INDIA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 140
  • TABLE 241 INDIA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 141
  • TABLE 242 INDIA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 141
  • TABLE 243 INDIA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 141
  • TABLE 244 INDIA: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 142
  • TABLE 245 JAPAN: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 142
  • TABLE 246 JAPAN: NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 142
  • TABLE 247 JAPAN: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 143
  • TABLE 248 JAPAN: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 143
  • TABLE 249 JAPAN: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2020-2027 (USD MILLION) 143
  • TABLE 250 JAPAN: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 144
  • TABLE 251 JAPAN: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2020-2027 (USD MILLION) 144
  • TABLE 252 JAPAN: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2020-2027 (USD MILLION) 144
  • TABLE 253 JAPAN: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2020-2027 (USD MILLION) 145
  • TABLE 254 JAPAN: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2020-2027 (USD MILLION) 145
  • TABLE 255 JAPAN: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 145
  • TABLE 256 JAPAN: NEUROPATHIC PAIN MARKET, BY END USER, 2020-2027 (USD MILLION) 146
  • TABLE 257 SOUTH KOREA: NEUROPATHIC PAIN MARKET, BY TYPE, 2020-2027 (USD MILLION) 146
  • TABLE 258 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2027 (USD MILLION) 146
  • TABLE 259 SOUTH KOREA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2020-2027 (USD MILLION) 147
  • TABLE 260 SOUTH KOREA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 147

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS 21
  • FIGURE 2 GLOBAL NEUROPATHIC PAIN MARKET 23
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 30
  • FIGURE 4 MARKET DYNAMICS: NEUROPATHIC PAIN MARKET 33
  • FIGURE 5 DRIVER IMPACT ANALYSIS 36
  • FIGURE 6 RESTRAINT IMPACT ANALYSIS 38
  • FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL NEUROPATHIC PAIN MARKET 39
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL NEUROPATHIC PAIN MARKET 41
  • FIGURE 9 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 46
  • FIGURE 10 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION, 2020 AND 2027 (USD MILLION) 51
  • FIGURE 11 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2020 AND 2027 (USD MILLION) 54
  • FIGURE 12 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT, 2020 AND 2027 (USD MILLION) 58
  • FIGURE 13 GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2020 AND 2027 (USD MILLION) 61
  • FIGURE 14 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 63
  • FIGURE 15 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 66
  • FIGURE 16 AMERICAS: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 67
  • FIGURE 17 NORTH AMERICA: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 72
  • FIGURE 18 EUROPE: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 90
  • FIGURE 19 WESTERN EUROPE: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 95
  • FIGURE 20 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 129
  • FIGURE 21 MIDDLE EAST & AFRICA: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 159
  • FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS 174
  • FIGURE 23 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL NEUROPATHIC PAIN MARKET 175
  • FIGURE 24 COMPETITIVE BENCHMARKING 176
  • FIGURE 25 SALES & OPERATING INCOME MARGIN, 2020 178
  • FIGURE 26 RESEARCH & DEVELOPMENT EXPENDITURE, 2020 178
  • FIGURE 27 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 180
  • FIGURE 28 ABBOTT: SWOT ANALYSIS 182
  • FIGURE 29 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 183
  • FIGURE 30 PFIZER INC.: SWOT ANALYSIS 184
  • FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 186
  • FIGURE 32 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 187
  • FIGURE 33 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW 188
  • FIGURE 34 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS 189
  • FIGURE 35 ELI LILY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 191
  • FIGURE 36 ELI LILY AND COMPANY: SWOT ANALYSIS 192
  • FIGURE 37 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 193
  • FIGURE 38 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 194
  • FIGURE 39 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 196
  • FIGURE 40 SANOFI: SWOT ANALYSIS 197
  • FIGURE 41 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 198
  • FIGURE 42 ASTRAZENECA: SWOT ANALYSIS 199
  • FIGURE 43 DEPOMED, INC.: FINANCIAL OVERVIEW SNAPSHOT 200
  • FIGURE 44 DEPOMED, INC.: SWOT ANALYSIS 201
  • FIGURE 45 BIOGEN, INC.: FINANCIAL OVERVIEW SNAPSHOT 202
  • FIGURE 46 BIOGEN: SWOT ANALYSIS 203
  • FIGURE 47 ASTELLAS PHARMA LTD.: FINANCIAL OVERVIEW SNAPSHOT 204
  • FIGURE 48 ASTELLAS PHARMA: SWOT ANALYSIS 205